Emma Andrus, Associate Editor

Click here to view Dermatology Times' comprehensive list of health awareness days, months, weeks, and initiatives for 2024.

Dermatology Times is reviewing some of the most anticipated PDUFA dates of the upcoming year.

Here is a look back at top Dermatology Times interviews with leading experts in dermatology this year.

Review Dermatology Times' top podcasts of 2023.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in acne this year.

Dermatology Times is reviewing some of the newest and largest studies coming out of this year.

Catch up on Dermatology Times conference coverage from July through December of this year.

Dermatology Times is reviewing the biggest news in the dermatology specialty this year.

Dermatology Times reviews updates and news surrounding this past year's allergen of the year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.

Dermatology Times reviews weekly editions of one of this year's new article segments, Derm in the News.

The analyses were published in the Journal of the European Academy of Dermatology and Venereology.

The most prevalent psychological disorder among patients was anxiety.

Researchers observed lower levels of serum gamma linolenic acid in patients with rosacea.

Investigators evaluated vitiligo punch grafting effectiveness on stable vitiligo lesions.

Sarkar spoke with Dermatology Times after the ReV conference to discuss her session on vitiligo stigma.

Chiesi Global Rare Diseases recently announced the approval of the topical treatment.

Click here to answer this week's poll about a recent FDA Complete Response Letter.

Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.

Keep up with the latest headlines in dermatology from the past week, including a new immuno-dermatology partnership, promising study results from a combined mRNA vaccine and Keytruda for advanced melanoma, and more.

Here is a recap of the drugs and treatments approved to keep in mind for the new year.

The confirmatory phase 3 trial demonstrated significant efficacy of TO-208 versus a placebo.

A poster from the RAD Virtual Conference reviewed the relationship between Black and DHH patients and the shared disparities these populations face.

Adbry (tralokinumab-LDRM) is now the first and only FDA-approved biologic for AD binding to and inhibiting IL-13.

Catch up on coverage from this week's virtual Revolutionizing Atopic Dermatitis and Revolutionizing Vitiligo conferences.

Lesional stability is a necessary requirement for determining the course of treatment for vitiligo.

The study evaluated the efficacy of AIV001 in superficial, nodular, and mixed BCC tumors.

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.